论文部分内容阅读
目的:研究乙肝转阴散(YGZYS)对HepG2.2.15细胞乙型肝炎表面抗原(HBsAg)和乙型肝炎E抗原(HBeAg)分泌的影响。方法:采用四甲基噻唑蓝(MTT)法检测YGZYS对HepG2.2.15细胞的半数毒性浓度(TC50)和最大无毒浓度(TC0);在TC0基础上观察药物5个不同浓度作用于HepG2.2.15细胞,采用酶联免疫吸附法(ELISA)测定培养4d和8d的细胞上清液HBsAg和HBeAg的滴度。结果:TC505.386g·L-1,TC00.736g·L-1。提示YGZYS对HepG2.2.15细胞毒性作用较低。在无毒浓度下,YGZYS能有效地抑制HepG2.2.15细胞分泌HBsAg和HBeAg;且治疗指数(TI)均大于2,说明YGZYS为高效低毒的抗HBV药物。结论:YGZYS可有效地抑制HepG2.2.15细胞HBsAg和HBeAg的分泌,且毒性较低。
Objective: To study the effect of YGZYS on the secretion of hepatitis B surface antigen (HBsAg) and hepatitis B E antigen (HBeAg) in HepG2.2.15 cells. Methods: The half toxic concentration (TC50) and maximum nontoxic concentration (TC0) of YGZYS on HepG2.2.15 cells were detected by MTT assay. Five different concentrations of YGZYS were tested on HepG2.2.15 The cell titers of HBsAg and HBeAg in the cell supernatants cultured for 4 days and 8 days were determined by enzyme-linked immunosorbent assay (ELISA). Results: TC505.386g · L-1, TC00.736g · L-1. Tip YGZYS HepG2.2.15 cytotoxicity is low. YGZYS could effectively inhibit the secretion of HBsAg and HBeAg in HepG2.2.15 cells at a non-toxic concentration; and the therapeutic index (TI) was greater than 2, indicating that YGZYS is a highly effective and low-toxic anti-HBV drug. Conclusion: YGZYS can effectively inhibit the secretion of HBsAg and HBeAg in HepG2.2.15 cells with low toxicity.